Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Phase 3Recruiting
- Sponsor
- Immatics
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Countries
- 6
01
Overview
A Phase 3 trial of PRAME TCR T cells in melanoma, sponsored by Immatics. Started Jan 2025; status: recruiting.
02
Drugs
PRAME TCR T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06743126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06743126.